Option Care Health, Inc. is a provider of home and alternate site infusion services in the United States. The company operates a national network of full-service pharmacies and ambulatory infusion suites to deliver intravenous therapies for complex and chronic medical conditions. Its services include clinical management, nursing support, and care coordination for treatments such as anti-infectives, nutrition support, immunoglobulin therapy, chronic inflammatory disorders, neurological disorders, and bleeding disorders. Option Care Health contracts with managed care organizations, third-party payers, hospitals, physicians, and pharmaceutical manufacturers to provide pharmaceuticals and compounded solutions. The company was formed in 2019 following the merger of BioScrip, Inc. and Option Care, Inc., the latter of which was acquired from Walgreens Co. in 2015 and rebranded. It also operates Naven Health, a nationwide home infusion nursing network and clinical platform focused on specialized infusion care.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Care Facilities Homepage optioncarehealth.com
Sector Healthcare IR page investors.optioncarehealth.com
Tags
home infusion, ambulatory infusion, anti-infectives, nutrition support, immunoglobulin therapy, chronic inflammatory disorders, neurological disorders, bleeding disorders, women's health, heart failure, clinical monitoring, care coordination, Naven Health
Press page —

Metrics

Valuation  
Market cap $ 4.741B
Market cap (USD) $ 4.741B
P/E 22.93
PEG 2.03
P/BV 3.58
P/S 0.82
P/OCF 14.72
P/FCF 16.83
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.2%
ROI 8.3%
ROIC 10.0%
Profit margin 3.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 11.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 87.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 5.65B 4.912B 4.302B 3.945B 3.439B 3.033B 2.31B 708.903M — — — — — — 1.818B 1.639B 1.33B 1.402B 1.198B 1.152B 1.073B 630.516M 588.77M 576.596M 456.646M —
Net profit 207.585M 211.823M 267.09M 150.556M 139.898M -8.076M -75.92M -51.693M -64.196M -41.506M -299.707M -147.468M -69.654M 64.707M 7.872M -69.142M 54.099M -74.032M 3.317M -38.289M -23.847M 7.033M 9.13M 18.685M 14.202M —
Free cash flow 217.14M 287.786M 329.429M 232.189M 182.937M 100.517M 11.175M — — — — — -337.551M -16.162M 26.506M -21.419M — — 18.661M -35.298M -11.551M 2.236M 13.382M 18.7M 8.294M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 31.86 23.2 33.69 30.09 28.44 15.64 3.73 3.57 2.91 1.04 1.75 6.99 7.4 10.77 5.8 5.22 — — — — — — — — — —
Price performance 12m 0.37 -0.31 0.12 0.06 0.82 3.19 0.04 0.23 1.8 -0.41 -0.75 -0.06 -0.31 0.86 0.11 — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 112M 85.5M 115M 324M 328M 338M 378M 378M 410M 474M
↳ YoY growth +3.2% -23.5% +34.3% +182.4% +1.2% +3.0% +11.6% +0.0% +8.5% +15.6%
↳ 5y CAGR -13.1% -7.9% -9.3% +18.2% +24.8% +24.8% +34.6% +26.9% +4.8% +7.6%
Borrowings, current (USD) 18.5M 1.72M 3.18M 9.25M 9.25M 6M 6M 6M 6.51M 6.78M
Borrowings, non-current (USD) 433M 479M 501M 1.28B 1.12B 1.06B 1.06B 1.06B 1.1B 1.15B
Lease liabilities (USD) — — 0.00 78.6M 89.7M 93.6M 90.8M 104M 107M 113M
Cash and deposits (USD) 9.57M 39.5M 14.5M 67.1M 99.3M 119M 294M 344M 413M 233M
Intangible assets (USD) 31M 19.1M 10.5M 386M 351M 366M 364M 335M 301M 309M
Right-of-use assets (USD) — — 0.00 63.5M 68.8M 74.8M 72.4M 84.2M 86.5M 91.3M
Net debt (borrowings + leases - cash) (USD) 442M 441M 490M 1.3B 1.11B 1.04B 861M 823M 805M 1.04B
Cash flow detail
Operating cash flow (USD) -42.8M -763,000 -20.1M 39.5M 127M 209M 268M 371M 323M 258M
Purchases of property, plant and equipment (USD) — -25M -26.3M -28.3M -26.9M -25.6M -35.4M -41.9M -35.6M -41.3M
Change in receivables (cash effect) (USD) -2.5M 23.6M -29.3M 82.3M -3.92M -4.27M -36.9M 224,000 -32.1M -54.6M
Change in inventories (cash effect) (USD) 10M -2.54M 11.4M -12.9M -42.7M -22.7M -41M -51M -114M -81.5M
Share buybacks (cash effect) (USD) — — — — — 0.00 0.00 -250M -253M -310M
Interest paid (cash effect) (USD) -34.7M -45.4M -41.5M -50.8M -97.6M -60.9M -50.4M -69.8M -71.6M -64.7M
Income taxes paid (cash effect) (USD) 372,000 -649,000 319,000 -2.41M -2.88M -5.71M -13.4M -75.2M -64.5M -67.3M
Share-based compensation (USD) 1.96M 2.36M 4.18M 4.17M 2.92M 9.58M 16.8M 30.5M 36.1M 40M
Operating cash flow before change in receivables (USD) -40.3M -24.3M 9.24M -42.8M 131M 213M 304M 371M 355M 313M
Free cash flow (OCF - PPE - intangibles) (USD) — 12.9M -1.85M 11.2M 101M 183M 232M 329M 288M 217M
Income detail
Total comprehensive income (USD) — 3.94M -5.34M -84M -12.1M 151M 172M 261M 208M 201M
Comprehensive income to owners (USD) — 3.94M -5.34M -84M -12.1M 151M 172M 261M 208M 201M
Provision for credit losses (USD) 26.8M 23.7M 0.00 0.00 — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 24.3% 24.0% 0.0% 0.0% — — — — — —
Reported Mar 7, 2017 Mar 5, 2020 Mar 5, 2020 Mar 5, 2020 Mar 11, 2021 Feb 22, 2024 Feb 22, 2024 Feb 22, 2024 Feb 26, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026 at 7:00 AM EST

PDF Version

BANNOCKBURN, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

(year-over-year comparisons unless otherwise noted)

  • Net revenue of $1,493.5 million, up 4.1%

  • GAAP net income of $57.4 million, up 10.8%

  • GAAP diluted earnings per share of $0.38, up 18.8%

  • Adjusted EBITDA of $124.6 million, up 4.3%

  • Adjusted diluted earnings per share of $0.49, up 8.9%

  • Cash provided by Q3 operating activities of $114.7 million

As previously announced, the Company has entered into a definitive merger agreement pursuant to which it will be acquired by Clayton, Dubilier & Rice, LLC and McKesson Corporation. Given the pending acquisition, the Company will not host an earnings conference call in connection with these results and has withdrawn its previously disclosed financial guidance.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

Investor Contact

Bob Okunski Vice President, Investor Relations [email protected]

Forward-Looking Statements - Safe Harbor

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company may make regarding the acquisition, future revenues, future earnings, other future financial results, regulatory developments, market developments, new products and growth strategies and the effects of any of the foregoing on its future results of operations or financial condition.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including circumstances requiring the Company to pay a termination fee pursuant to the merger agreement, or the inability to complete the proposed transaction on the anticipated terms and timetable; the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of the Company or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; costs related to the proposed transaction, including from potential litigation relating to the proposed transaction; the risk that restrictions on the operation of the Company’s business during the pendency of the proposed transaction may impact the Company’s ability to pursue certain business opportunities or strategic transactions or undertake certain actions the Company might otherwise have taken; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s common stock, credit ratings or operating results; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel, retain customers and maintain relationships with business partners, suppliers and customers; the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction; changes in laws, regulations or trade policies applicable to its business model; loss of relationships with managed care organizations and other non-governmental third party payers; changes in the pharmaceutical industry, including limiting or discontinuing research, development, production and marketing of pharmaceuticals compatible with its services; changes in market conditions and receptivity to its services and offerings; and pending and future litigation or potential liability for claims not covered by insurance. The foregoing review of important factors should not be construed as exhaustive. Additional information concerning risks, uncertainties and assumptions can be found in the Company’s filings with the SEC, including the risk factors discussed in the Company’s most recent Annual Report on Form 10-K, as updated by the Company’s Quarterly Reports on Form 10-Q and future filings with the SEC.

Any forward-looking statement made by the Company in this press release is based only on information currently available to it and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted earnings per share ("EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, EPS, or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted diluted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted net income represents net income before intangible asset amortization expense, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments, (ii) Adjusted EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted diluted EPS represents Adjusted net income divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration and other expenses, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that these adjusted measures provide useful supplemental information regarding the performance of Option Care Health’s business operations and facilitate comparisons to the Company’s historical operating results. The Company has not reconciled Adjusted EBITDA guidance to net income or Adjusted diluted EPS guidance to GAAP diluted EPS as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each historical adjusted measure to the most comparable GAAP financial measure are set forth below.

| | | | |

| | Schedule 1 |

| OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)(UNAUDITED) |

| | | | |

| | September 30, 2026 | | December 31, 2025 |

| ASSETS | | | |

| CURRENT ASSETS: | | | |

| Cash and cash equivalents | $ | 299,093 | | $ | 232,624 |

| Accounts receivable, net | | 505,568 | | | 473,566 |

| Inventories | | 408,045 | | | 471,149 |

| Prepaid expenses and other current assets | | 99,385 | | | 87,629 |

| Total current assets | | 1,312,091 | | | 1,264,968 |

| | | | |

| NONCURRENT ASSETS: | | | |

| Property and equipment, net | | 139,035 | | | 139,236 |

| Intangible assets, net | | 19,394 | | | 21,897 |

| Referral sources, net | | 261,975 | | | 287,281 |

| Goodwill | | 1,606,743 | | | 1,606,743 |

| Other noncurrent assets | | 137,029 | | | 135,644 |

| Total noncurrent assets | | 2,164,176 | | | 2,190,801 |

| TOTAL ASSETS | $ | 3,476,267 | | $ | 3,455,769 |

| | | | |

| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |

| CURRENT LIABILITIES: | | | |

| Accounts payable | $ | 670,676 | | $ | 639,829 |

| Other current liabilities | | 179,854 | | | 189,519 |

| Total current liabilities | | 850,530 | | | 829,348 |

| | | | |

| NONCURRENT LIABILITIES: | | | |

| Long-term debt, net of discount, deferred financing costs and current portion | | 1,151,054 | | | 1,154,052 |

| Other noncurrent liabilities | | 150,205 | | | 145,976 |

| Total noncurrent liabilities | | 1,301,259 | | | 1,300,028 |

| Total liabilities | | 2,151,789 | | | 2,129,376 |

| | | | |

| STOCKHOLDERS' EQUITY | | 1,324,478 | | | 1,326,393 |

| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 3,476,267 | | $ | 3,455,769 |

| |

| Schedule 2 |

| |

| OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| NET REVENUE | $ | 1,493,529 | | | $ | 1,435,016 | | | $ | 4,286,583 | | | $ | 4,184,073 | |

| COST OF REVENUE | | 1,208,555 | | | | 1,162,114 | | | | 3,472,344 | | | | 3,379,076 | |

| GROSS PROFIT | | 284,974 | | | | 272,902 | | | | 814,239 | | | | 804,997 | |

| | | | | | | | |

| OPERATING COSTS AND EXPENSES: | | | | | | | |

| Selling, general and administrative expenses | | 171,998 | | | | 167,470 | | | | 503,063 | | | | 497,744 | |

| Restructuring, acquisition, integration and other | | 5,640 | | | | 4,634 | | | | 13,796 | | | | 12,570 | |

| Depreciation and amortization expense | | 18,120 | | | | 16,291 | | | | 50,479 | | | | 48,278 | |

| Total operating expenses | | 195,758 | | | | 188,395 | | | | 567,338 | | | | 558,592 | |

| OPERATING INCOME | | 89,216 | | | | 84,507 | | | | 246,901 | | | | 246,405 | |

| | | | | | | | |

| OTHER INCOME (EXPENSE): | | | | | | | |

| Interest expense, net | | (12,875 | ) | | | (14,146 | ) | | | (40,199 | ) | | | (41,824 | ) |

| Other, net | | 2,560 | | | | (1,394 | ) | | | 7,189 | | | | (3,197 | ) |

| Total other (expense) income | | (10,315 | ) | | | (15,540 | ) | | | (33,010 | ) | | | (45,021 | ) |

| | | | | | | | |

| INCOME BEFORE INCOME TAXES | | 78,901 | | | | 68,967 | | | | 213,891 | | | | 201,384 | |

| INCOME TAX EXPENSE | | 21,468 | | | | 17,151 | | | | 57,202 | | | | 52,303 | |

| NET INCOME | $ | 57,433 | | | $ | 51,816 | | | $ | 156,689 | | | $ | 149,081 | |

| | | | | | | | |

| Earnings per share, basic | $ | 0.38 | | | $ | 0.32 | | | $ | 1.02 | | | $ | 0.91 | |

| Earnings per share, diluted | $ | 0.38 | | | $ | 0.32 | | | $ | 1.02 | | | $ | 0.91 | |

| | | | | | | | |

| Weighted average shares outstanding, basic | | 149,788 | | | | 161,829 | | | | 153,099 | | | | 163,393 | |

| Weighted average shares outstanding, diluted | | 150,491 | | | | 163,086 | | | | 153,932 | | | | 164,602 | |

| | |

| Schedule 3 |

| | |

| OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)(UNAUDITED) |

| | |

| | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | |

| CASH FLOWS FROM OPERATING ACTIVITIES: | | | |

| Net income | $ | 156,689 | | | $ | 149,081 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | |

| Depreciation and amortization expense | | 52,874 | | | | 50,374 | |

| Other non-cash adjustments | | 54,243 | | | | 57,401 | |

| Changes in operating assets and liabilities: | | | |

| Accounts receivable, net | | (32,002 | ) | | | (55,430 | ) |

| Inventories | | 63,104 | | | | (24,899 | ) |

| Prepaid expenses and other current assets | | (14,933 | ) | | | 24,694 | |

| Accounts payable | | 31,824 | | | | 10,224 | |

| Accrued compensation and employee benefits | | (8,069 | ) | | | 8,338 | |

| Other | | (17,518 | ) | | | 2,773 | |

| Net cash provided by operating activities | | 286,212 | | | | 222,556 | |

| | | | |

| CASH FLOWS FROM INVESTING ACTIVITIES: | | | |

| Acquisition of property and equipment | | (26,805 | ) | | | (27,661 | ) |

| Business acquisitions, net of cash acquired | | — | | | | (117,247 | ) |

| Other investing activities | | (877 | ) | | | (2,529 | ) |

| Net cash used in investing activities | | (27,682 | ) | | | (147,437 | ) |

| | | | |

| CASH FLOWS FROM FINANCING ACTIVITIES: | | | |

| Purchase of company stock and related excise taxes | | (170,545 | ) | | | (214,887 | ) |

| Proceeds from issuance of debt | | — | | | | 229,472 | |

| Retirement of debt obligations | | — | | | | (180,239 | ) |

| Other financing activities | | (21,516 | ) | | | (12,208 | ) |

| Net cash used in financing activities | | (192,061 | ) | | | (177,862 | ) |

| | | | |

| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | | 66,469 | | | | (102,743 | ) |

| Cash and cash equivalents - beginning of period | | 232,624 | | | | 412,565 | |

| CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 299,093 | | | $ | 309,822 | |

| |

| Schedule 4 |

| |

| OPTION CARE HEALTH, INC. QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net income | $ | 57,433 | | | $ | 51,816 | | | $ | 156,689 | | | $ | 149,081 | |

| Interest expense, net | | 12,875 | | | | 14,146 | | | | 40,199 | | | | 41,824 | |

| Income tax expense | | 21,468 | | | | 17,151 | | | | 57,202 | | | | 52,303 | |

| Depreciation and amortization expense | | 18,837 | | | | 17,048 | | | | 52,874 | | | | 50,374 | |

| EBITDA | | 110,613 | | | | 100,161 | | | | 306,964 | | | | 293,582 | |

| | | | | | | | |

| EBITDA adjustments | | | | | | | |

| Stock-based incentive compensation expense | | 9,331 | | | | 11,125 | | | | 27,912 | | | | 30,638 | |

| Loss on extinguishment of debt | | — | | | | 4,744 | | | | — | | | | 4,744 | |

| Restructuring, acquisition, integration and other (1) | | 4,656 | | | | 3,468 | | | | 11,976 | | | | 16,318 | |

| Adjusted EBITDA | $ | 124,600 | | | $ | 119,498 | | | $ | 346,852 | | | $ | 345,282 | |

| | | | | | | | |

| Net income | $ | 57,433 | | | $ | 51,816 | | | $ | 156,689 | | | $ | 149,081 | |

| Intangible asset amortization expense | | 9,269 | | | | 9,269 | | | | 27,808 | | | | 27,663 | |

| Stock-based incentive compensation expense | | 9,331 | | | | 11,125 | | | | 27,912 | | | | 30,638 | |

| Loss on extinguishment of debt (2) | | — | | | | 4,744 | | | | — | | | | 4,744 | |

| Restructuring, acquisition, integration and other (1) | | 4,656 | | | | 3,468 | | | | 11,976 | | | | 16,318 | |

| Total pre-tax adjustments | | 23,256 | | | | 28,606 | | | | 67,696 | | | | 79,363 | |

| Tax adjustments (3) | | (6,298 | ) | | | (7,183 | ) | | | (18,075 | ) | | | (20,634 | ) |

| Adjusted net income | $ | 74,391 | | | $ | 73,239 | | | $ | 206,310 | | | $ | 207,810 | |

| | | | | | | | |

| Earnings per share, diluted | $ | 0.38 | | | $ | 0.32 | | | $ | 1.02 | | | $ | 0.91 | |

| Adjusted earnings per share, diluted | $ | 0.49 | | | $ | 0.45 | | | $ | 1.34 | | | $ | 1.26 | |

| Weighted average common shares outstanding, diluted | | 150,491 | | | | 163,086 | | | | 153,932 | | | | 164,602 | |

| | | | | | | | | | | | | | | | |

(1) Restructuring, acquisition, integration and other includes $5,640 and $13,796 of operating expenses for the three and nine months ended September 30, 2026, respectively. Restructuring, acquisition, integration and other includes $4,634 and $12,570 of operating expenses for the three and nine months ended September 30, 2025, respectively.

(2) Beginning with the three months ended September 30, 2025, adjusted net income excludes loss on extinguishment of debt on a prospective basis, which has been immaterial in prior periods.

(3) Tax adjustments for the three and nine months ended September 30, 2026 and 2025 include the estimated income tax effect on non-GAAP adjustments based on the effective tax rate.

Primary Logo

Source: Option Care Health, Inc.

October 6, 2026 at 8:00 AM EDT

PDF Version

NEW YORK & IRVING, Texas & BANNOCKBURN, Ill.--(BUSINESS WIRE)--Oct. 6, 2026-- CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have entered into a definitive agreement, under which CD&R and McKesson will acquire Option Care Health, an independent provider of home and alternate site infusion services, for $32.05 per share, reflecting a total enterprise value of approximately $5.8 billion. At the closing of the transaction, CD&R will hold a majority ownership interest, and McKesson will hold a minority ownership interest. Option Care Health will remain a separate company led by its own management team.

“We are pleased to have entered into this agreement, which provides immediate cash value for our stockholders,” said Harry Kraemer, Chairman of the Board of Option Care Health. “The Board of Directors completed an extensive assessment, involving thorough discussions with our advisors, and unanimously concluded this transaction maximizes value for our stockholders.”

“This transaction represents a great outcome for Option Care Health and our stockholders, and I want to thank our Board of Directors for their rigorous process and diligence,” said John C. Rademacher, Chief Executive Officer of Option Care Health. “For more than 45 years, Option Care Health has helped transform the way infusion therapy is delivered, led by our team members’ unwavering commitment to providing extraordinary care to patients. We will continue to enhance our platform and deepen our partnerships with hospitals and health systems, physicians, payers, and biopharma manufacturers. We are thrilled to have the support of CD&R and McKesson, empowering us to continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care. Both firms understand our business and the healthcare industry, and have proven track records of fostering growth for some of the largest and fastest-growing healthcare service businesses globally.”

“Option Care Health has shown what is possible when high-quality infusion therapy is delivered where patients are most comfortable: at home and in their communities,” said CD&R Partner Sarah Kim. “We look forward to supporting Option Care Health’s proven management team, together with McKesson and applying CD&R’s deep experience in healthcare services to help Option Care Health bring specialized therapies to more patients across the country.”

“This investment represents an important opportunity that aligns with McKesson’s long-term strategy to expand access and affordability to innovative therapies across the care continuum,” said Brian Tyler, Chair and Chief Executive Officer of McKesson. “As these therapies continue to grow in importance and their delivery becomes increasingly complex, McKesson is focused on investing in areas where our capabilities can help improve access and advance care in lower-cost community settings, at or closer to home. Option Care Health’s clinical model and national infusion footprint across home and ambulatory sites are well aligned with those priorities, and the company is well positioned for continued growth. As a strategic investor, we look forward to bringing McKesson’s experience and expertise in specialty pharmaceuticals to support Option Care Health’s strategy of broadening access to complex therapies and enabling care delivery in lower-cost settings, while creating long-term value for stakeholders.”

The transaction aligns with McKesson’s strategic objectives:

  • Positioned for growth in specialty care: Continued innovation in specialty, rare and orphan therapies and the increasing need for alternate infusion services represent an attractive long-term growth opportunity to support community providers, health systems, payers, and biopharma companies. Through this investment, McKesson will support the delivery of complex specialty therapies across multiple care settings.

  • Expanded patient access through community-based care: Option Care Health’s home and ambulatory infusion capabilities help patients access complex therapies outside traditional care settings, aligning with McKesson’s focus to allow accessible and affordable high-quality care to patients.

Option Care Health will continue to operate as usual, with the same commitment to its patients, providers, employees, and partners.

Transaction Details, Timing, and Approvals

Under the definitive agreement, CD&R will hold a majority interest of approximately 51% in Option Care Health and McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. The transaction also establishes a framework for McKesson’s future acquisition of CD&R’s interest in Option Care Health, subject to specified conditions and regulatory approvals. Following the closing of the transaction, McKesson intends to account for its minority interest in Option Care Health using the equity method of accounting, recording its share of Option Care Health’s net income or loss in Other Income, net.

The transaction value represents a premium of approximately 37% to Option Care Health’s closing share price on October 5, 2026, the last full trading day of Option Care Health’s common stock prior to the transaction announcement.

The transaction is expected to close in the first half of calendar year 2027, subject to customary closing conditions, including approval by Option Care Health’s stockholders and the receipt of required regulatory approvals.

Upon completion of the transaction, Option Care Health’s common stock will no longer be publicly listed on the Nasdaq Stock Exchange, and Option Care Health will become a privately held company.

Option Care Health Third Quarter 2026 Financial Results and 2026 Guidance

Option Care Health expects to release its financial results for the third quarter ended September 30, 2026, on November 4, 2026. Given the transaction announcement, Option Care Health will not host a live conference call in conjunction with its third quarter earnings release and is also withdrawing its previously disclosed financial guidance.

Advisors

Centerview Partners LLC is serving as financial advisor, Kirkland & Ellis LLP is serving as legal advisor, and Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor to Option Care Health. BofA Securities, Barclays, Goldman Sachs, Jefferies, and Wells Fargo are acting as financial advisors on this transaction and are also providing committed financing to the consortium. Debevoise & Plimpton LLP is serving as legal advisor to CD&R. Davis Polk & Wardwell LLP and Reed Smith LLP are serving as McKesson’s legal advisors.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

About CD&R

Founded in 1978, CD&R is a leading private investment firm with a strategy of generating strong investment returns by building more robust and sustainable businesses through the combination of skilled investment experience and deep operating capabilities. In partnership with the management teams of its portfolio companies, CD&R takes a long-term view of value creation and emphasizes positive stewardship and impact. The firm invests in businesses that span a broad range of industries, including industrial, healthcare, consumer, technology and financial services end markets. CD&R is privately owned by its partners and has offices in New York and London. For more information, please visit www.cdr.com and follow the firm’s activities through LinkedIn.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

Additional Information and Where to Find It

In connection with the proposed acquisition and related transactions (collectively, the “proposed transaction”) involving Option Care Health and affiliates of CD&R and McKesson (collectively, the “Investor Group”), Option Care Health will file a preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”). Option Care Health plans to mail a definitive proxy statement (the “Proxy Statement”) to Option Care Health’s stockholders.

OPTION CARE HEALTH’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Investors and security holders will be able to obtain a free copy of the Proxy Statement (when available) as well as other documents filed by Option Care Health with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Option Care Health will be available free of charge on Option Care Health’s internet website at optioncarehealth.com or by contacting Option Care Health’s investor relations department at [email protected].

Certain Information Regarding Participants in the Solicitation

Option Care Health and its directors and executive officers may be considered participants in the solicitation of proxies from Option Care Health’s stockholders in connection with the proposed transaction. Information about the directors and executive officers of Option Care Health is set forth in its proxy statement for its 2026 annual meeting of stockholders, which was filed with the SEC on April 8, 2026 (the “Annual Meeting Proxy Statement”). To the extent the holdings of Option Care Health’s securities by its directors or executive officers have changed since the amounts set forth in the Annual Meeting Proxy Statement, such changes have been or will be reflected on Forms 3, 4 and 5 filed with the SEC.

Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, in the proposed transaction will be contained in the proxy statement that Option Care Health expects to file and in other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) as described above.

Cautionary Statement Regarding Forward-Looking Statements - Option Care Health

This communication may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include statements regarding the proposed transaction, stockholder approval and the expected benefits of and timeline for completing the proposed transaction.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s beliefs, expectations and assumptions at the time that these statements were prepared. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Option Care Health’s control. Option Care Health’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. These factors include, but are not limited to: (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including circumstances requiring Option Care Health to pay a termination fee pursuant to the merger agreement, or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of Option Care Health or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) costs related to the proposed transaction, including from potential litigation relating to the proposed transaction, (4) the risk that restrictions on the operation of Option Care Health’s business during the pendency of the proposed transaction may impact Option Care Health’s ability to pursue certain business opportunities or strategic transactions or undertake certain actions Option Care Health might otherwise have taken, (5) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Option Care Health’s common stock, credit ratings or operating results, (6) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Option Care Health to retain and hire key personnel, retain customers and maintain relationships with business partners, suppliers and customers and (7) the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in Option Care Health’s filings with the SEC, including the risk factors discussed in Option Care Health’s most recent Annual Report on Form 10-K, as updated by Option Care Health’s Quarterly Reports on Form 10-Q and future filings with the SEC.

Any forward-looking statement made in this communication is based only on information currently available to Option Care Health and speaks only as of the date on which it is made. Option Care Health undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. You are cautioned not to rely on Option Care Health’s forward-looking statements.

Cautionary Statements - McKesson Corporation

Except for historical information, statements in this press release regarding McKesson’s proposed minority investment in Option Care Health, the proposed acquisition of Option Care Health by the CD&R-controlled investment vehicle and related arrangements constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, McKesson undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in McKesson’s publicly available filings with the Securities and Exchange Commission. These risks include, but are not limited to: the parties may be unable to obtain required stockholder or regulatory approvals or satisfy other closing conditions; the transaction may be delayed or may not be completed; McKesson may not achieve the expected benefits of its investment; Option Care Health may not achieve the expected growth or other outcomes described in this release; McKesson may record impairment or other charges relating to its investment; and the parties’ ownership structure may adversely affect the transaction, industry relationships or the businesses involved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261005837505/en/

Option Care Health Investors Bob Okunski [email protected]

Media Relations Sharon Stern / Arielle Rothstein / Allison Sobel Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

CD&R External Affairs Jon Selib [email protected]

McKesson Corporation Investors [email protected]

Media Relations [email protected]

Source: McKesson Corporation and CD&R and Option Care Health, Inc.

September 2, 2026 at 4:05 PM EDT

PDF Version

BANNOCKBURN, Ill., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced that John Rademacher, CEO and Meenal Sethna, CFO, will participate in the following up coming investor conferences:

  • Morgan Stanley 24th Annual Global Healthcare Conference, being held in New York City, on Tuesday, September 15, 2026 at 10:45am ET/9:45am CT.

  • Deutsche Bank 2026 Healthcare Summit, being held in New York City, Wednesday, September 16, 2026.

Webcast links and related presentation materials, if applicable, will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

For Investor Inquiries:

Bob Okunski Vice President, Investor Relations [email protected]

Primary Logo

Prompts

Option Care Health, Inc. (ticker OPCH), listed in United States.

Company History

Date Change Detail
Aug 7, 2019 Renamed BIOSCRIP, INC. → OPTION CARE HEALTH, INC.
Mar 14, 2005 Renamed MIM CORP → BIOSCRIP, INC.

ETFs Holding Option Care Health, Inc.

ETF Weight in ETF Shares Market value As of
SOVF 2.75% 104,151 $ 2.399M Jul 31, 2026
ABCS 1.04% 5,557 $ 130.312K Aug 31, 2026
TSME 0.91% 455,235 $ 9.546M Jun 30, 2026
FSEV 0.71% 2,263 $ 47.455K Jun 30, 2026
IVSS 0.60% 7,676 $ 160.966K Jun 30, 2026
FESM 0.57% 1,582,208 $ 33.179M Jun 30, 2026
DSMC 0.57% 34,823 $ 730.238K Jun 30, 2026
FSEG 0.41% 1,120 $ 23.486K Jun 30, 2026
BTAL 0.41% 54,648 $ 1.146M Jun 30, 2026
SCDS 0.24% 682 $ 21.572K Nov 17, 2026
AVSC 0.22% 218,979 $ 6.944M Nov 16, 2026
JMEE 0.19% 167,686 $ 5.304M Nov 17, 2026
RUSC 0.16% 6,097 $ 127.854K Jun 30, 2026
RESM 0.15% 264 $ 5,536.08 Jun 30, 2026
PSC 0.14% 157,911 $ 3.311M Jun 30, 2026
FEAC 0.05% 562 $ 11.785K Jun 30, 2026
MSSM 0.01% 4,089 $ 95.887K Aug 31, 2026
EBI 0.00% 6 $ 140.70 Aug 31, 2026
FELV 0.00% 28 $ 587.16 Jun 30, 2026
FELC 0.00% 64 $ 1,342.08 Jun 30, 2026